Q-omics provides the consensus-scored CT47B1 profile across patient tissues and cancer cell-line models. CT47B1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CT47B1 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, CT47B1 RNA expression shows 5,523 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, LIHC, and STAD as cancer lineages where CT47B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CT47B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CT47B1 survival associations across molecular data types. CT47B1 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CT47B1 RNA expression–survival associations across cancer types. High CT47B1 expression shows unfavorable associations in KIRP, KICH, READ, STAD, UCS and DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CT47B1 RNA expression.
This table summarizes CT47B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CT47B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CT47B1 shows higher tumor expression in LIHC and PRAD. The LIHC box plot shows higher CT47B1 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .002).
This table shows molecular features associated with CT47B1 in patient tissues and cancer cell lines. In patient samples, CT47B1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CT47B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Myeloma.
